tailieunhanh - Báo cáo y học: "Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học quốc tế cung cấp cho các bạn kiến thức về ngành y đề tài: " Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models | Theoretical Biology and Medical Modelling BioMed Central Open Access Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic WB-PBPK models Michaela Vossen1 Michael Sevestre2 Christoph Niederalt1 In-Jin Jang3 Stefan Willmann1 and Andrea N Edginton 1 Address Competence Center Systems Biology Bayer Technology Services GmbH 51368 Leverkusen Germany Competence Center Computational Solutions Bayer Technology Services GmbH 51368 Leverkusen Germany and Department of Pharmacology and Clinical Pharmacology Unit Seoul National University College of Medicine and Hospital Seoul South Korea Email Michaela Vossen - Michael Sevestre - Christoph Niederalt - In-Jin Jang - ijjang@ Stefan Willmann - Andrea N Edginton - Corresponding author Published 26 March 2007 Received 15 February 2007 Theoretical Biology and Medical Modelling 2007 4 13 doi 1742-4682-4-13 Accepted 26 March 2007 This article is available from http content 4 1 13 2007 Vossen et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Drug-drug interactions resulting from the inhibition of an enzymatic process can have serious implications for clinical drug therapy. Quantification of the drugs internal exposure increase upon administration with an inhibitor requires understanding to avoid the drug reaching toxic thresholds. In this study we aim to predict the effect of the CYP3A4 inhibitors itraconazole ITZ and its primary metabolite .